Collplant Biotechnologies Ltd ADR CLGN

$3.97 +0.51 (14.74%)

Valuation

Market cap
6,542,000
Revenue TTM
$2,370,000
Net income TTM
$-11,490,000
PE ratio
0.00
Forward PE
—
Profit margin
-484.81%
Debt to equity
0.00

Trading

Volume
57,300
Avg volume
451,408
Day's range
$3.31 – $4.16
Shares out
1,891,000
Stochastic %K
69%
Beta
1.77
Analysts
Strong Sell
Price target
$110.00

Price

Company profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue filler...

Show more

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 73 232 5600
Website
https://collplant.com
Address
Weizmann Science Park, 4 Oppenheimer P.O. Box 4132, Rehovot, Israel

Latest news

Stocktwits

Monty_Roysiin Oct 8, 7:33 PM
$CTSO $BRTX $AIXI $TANH $CLGN j
1 replies
QES Oct 7, 2:19 PM
$CLGN shareholders deserve answers on executive compensation. Reported 2024 annual salary costs: — CEO Yehiel Tal: $540K — Deputy CEO/CFO Eran Rotem: $422K — VP Philippe Bensimon: $242K Total: $1.204M, before separately reported bonuses and option awards. 2025 revenue: $2.371M. First-half 2026 revenue: just $181K. AbbVie agreement: terminated. Workforce cuts: approximately 25% in November 2025, followed by another approximately 50% announced in April 2026. Yet I haven’t found a public commitment to executive salary cuts. These are historical compensation figures—not confirmed 2026 pay. But shareholders deserve to know: What are executives earning NOW, and how much have they cut their own compensation while cutting staff?
0 replies
Jessypenny Oct 7, 8:41 AM
$CLGN https://finance.yahoo.com/technology/ai/articles/lightsolver-files-u-provisional-patent-110000131.html
0 replies
focafoca99 Oct 6, 12:18 PM
$CLGN noted its filing of a US provisional patent for LightSolver's photonic computing platform.
1 replies
champinnow Oct 5, 7:45 PM
$PHRRF This is a good step forward: Strategic Assets Its FDA-approved ketamine ANDA, sale US$25 million over time, subject to commercial performance, with payments expected to begin in Q1 2027. Upcoming Milestones Q4 2026: initial CraftMake™ orders; first proprietary 503A product launches; initial white-label and CDMO agreements; orphan drug and rare pediatric disease designation applications. Q1 2027: ketamine dissolvable tablet launch for telehealth; first ketamine ANDA payments expected; pre-IND meeting with the FDA on the rare pediatric program. Next 12 months: up to 50 CraftMake™ placements; telehealth partnerships and further white-label and CDMO agreements; national emergency demonstration. 2027–2028: M3DICINES™ formulation licences; government readiness contracts; an expanded product portfolio, including ultra-rare disease, psychedelic Q4 2028: rare pediatric NDA submission (target). $CLGN $DDD $SSYS
0 replies
QES Sep 29, 7:24 PM
$CLGN I suspect the best PR we could get is if CLGN signed a collagen contract and made money, preferable a big contract. Then there would be cash, the number one thing this combination of two cash-starved companies united, needs.
0 replies
QES Sep 24, 3:42 PM
$CLGN LightSolver and the High-Performance Computing Center Stuttgart paper shows striking results: across the problems tested, the study projects LPU time-to-solution acceleration from roughly 40× to more than 80,000×. Note that these results were produced using an emulator rather than the finished commercial LPU hardware. Nevertheless, the comparison was conducted jointly with HLRS, one of Europe's major supercomputing centers, and subjected to peer review. That makes it substantially more consequential than a LightSolver marketing benchmark. It directly addresses the absence of independent technical validation for LightSolver's extraordinary performance claims. The physical LPU still needs to demonstrate comparable performance, but it should reduce it. The particularly interesting range is not merely the 80,000× headline. Even the low end, approx 40× would be commercially important if eventually demonstrated on physical hardware at competitive cost and power consumption.
0 replies
SmartMoneyTradez Sep 24, 12:36 PM
$CLGN crazy bid/ask
0 replies